Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Telix Pharmaceuticals ( (AU:TLX) ) has provided an announcement.
Telix Pharmaceuticals reported unaudited full-year 2025 revenue of approximately US$804 million, meeting its upgraded guidance and reflecting strong growth in its Precision Medicine business, which generated US$161 million in the fourth quarter driven by the successful reimbursed U.S. launch of Gozellix. The company also advanced its therapeutics pipeline, initiating or progressing multiple clinical trials in prostate, kidney and brain cancers, and bone metastasis pain, while entering a strategic collaboration with Varian to explore combinations of its radiopharmaceuticals with external beam radiation therapy, underscoring Telix’s ambition to solidify its position as a leader in radiopharmaceutical oncology and support sustained growth in 2026 and beyond.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a radiopharmaceutical company focused on precision oncology, developing and commercializing diagnostic and therapeutic products that target cancers such as prostate, renal and brain tumors. Its precision medicine business is anchored by radiopharmaceutical imaging agents like Illuccix and the newly launched Gozellix, with a growing pipeline of therapeutic candidates aimed at leveraging targeted radiation to address significant unmet medical needs in oncology across global markets.
YTD Price Performance: 0.71%
Average Trading Volume: 1,741,342
Technical Sentiment Signal: Sell
Current Market Cap: A$3.89B
See more data about TLX stock on TipRanks’ Stock Analysis page.